Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mevacor, Pravachol Rx-To-OTC Switches To Be Considered In July

Executive Summary

Rx-to-OTC switch applications for the cholesterol-lowering drugs Mevacor and Pravachol will be reviewed during joint meetings of the Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees July 13 and 14.

You may also be interested in...



Statin OTC Switch Debate Reflects Poorly On Physicians - FDA's Woodcock

The discussion of switching cholesterol agents to over-the-counter status may reflect the failure of physicians to provide adequate counseling to patients, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, told the agency's OTC switch public hearing June 29.

Statin OTC Switch Debate Reflects Poorly On Physicians - FDA's Woodcock

The discussion of switching cholesterol agents to over-the-counter status may reflect the failure of physicians to provide adequate counseling to patients, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, told the agency's OTC switch public hearing June 29.

New Merck Research VP Greene Has Advisory Committee Experience

Douglas Greene, MD, joins Merck Research Laboratories as executive VP-clinical sciences & product development with prior experience serving on FDA's Endocrinologic & Metabolic Drugs Advisory Committee.

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel